Artiva Biotherapeutics, Inc. — Form 8-K
Filed September 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Artiva Biotherapeutics amended its 2024 Equity Incentive Plan (adopted July 11, 2024; amended July 15, 2026) to establish a total Share Reserve of 13,328,057 shares comprised of: 823,096 shares approved at 2026 Annual Meeting; 1,214,580 from 2025 Annual Meeting; 2,630,000 initial reserve; 115,436 from Prior Plan; two annual automatic 5% increases (1,214,580 in Jan 2025; 1,229,777 in Jan 2026); 5,097,095 approved at 2026 Annual Meeting; and up to 1,826,589 Returning Shares. The plan provides for further automatic 5% annual increases through January 1, 2034. No counterparties or dollar amounts specified; no specific grant dates or recipient counts disclosed.
Why this rating
At $15M market cap, 13.3M share reserve is approximately 89% of market value—highly material. Successive amendments and automatic increases create substantial dilution risk. However, plan structure itself is administrative rather than a discrete business event; impact depends on actual grant timing and recipient identity not disclosed herein.
Price action (we called it neutral)
before filing · preread $10.22 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.